Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA Apr 08 | 2020Trulicity CV Protection DTC Initiated; Lilly Announces $35 Co-Pay for COVID-19 HelpPurchase Blast$599
Posted in: Allogeneic, Autologous, CAR-T, CD123, CD19, CD22, CS1 Apr 08 | 2020Cellectis Q4 '19 Earnings UpdatePurchase Blast$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CS1 Apr 08 | 2020Kite Acquires Rights to Certain Teneobio Antibodies for Multiple Myeloma CAR-T Therapies (including BCMA)Purchase Blast$599
Posted in: Glucose Monitoring Apr 03 | 2020CGM: Thoughts on Lifescan/Sanvita CGM Trial Impact from COVID-19Purchase Blast$599
Posted in: Basal Insulin Apr 01 | 2020Biocon's Malaysian Facility Passes Pre-Approval Glargine FDA InspectionPurchase Blast$599
Posted in: Glucagon Mar 31 | 2020Glucagon: Zealand Submits NDA for Dasiglucagon HypoPal Rescue PenPurchase Blast$599
Posted in: GLP-1RA Mar 27 | 2020FENIX Analysis: Ozempic and Trulicity CV Indication Initial PromotionPurchase Blast$599
Posted in: Glucose Monitoring Mar 26 | 2020Senseonics Suspends US Commercial Sales to New PatientsPurchase Blast$599
Posted in: Other Mar 25 | 2020AZ Partners with Silence Therapeutics for siRNA Targeting; AZ Leverages BrightInsight for Digital PlatformPurchase Blast$599
Posted in: Glucose Monitoring Mar 24 | 2020DarioHealth Partners with Vitality GroupPurchase Blast$599
Posted in: Glucose Monitoring Mar 23 | 2020Senseonics Exploring Strategic AlternativesPurchase Blast$599
Posted in: Dual/triple agonist, Other Mar 23 | 2020BI Returns Amylin Analog WW Rights to ZealandPurchase Blast$599
Posted in: Bolus Insulin, GLP-1RA Mar 23 | 2020CHMP Agenda March 23-26; Lilly Halts Trial Enrollments Over COVID-19 ConcernsPurchase Blast$599
Posted in: Glucagon, Insulin Delivery, Other Mar 20 | 2020Glooko Enables Free Remote Care Solution; Hovorka’s AP App Launched in UK; Valeritas Receives Court Approval on Zealand SalePurchase Blast$599
Posted in: Bolus Insulin, Glucagon Mar 19 | 2020Xeris Home Delivery via Amazon; Oramed End-of-Ph2 FDA FeedbackPurchase Blast$599
Posted in: Other Mar 18 | 2020Medtronic To Move Away From Its Non-Intensive Diabetes StrategyPurchase Blast$599
Posted in: Glucose Monitoring Mar 18 | 2020Nemaura to Use Wellness Category for US CGM LaunchPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.